We conducted an epigenome-wide association study on obesity-related traits. We used data from 2 prospective, population-based cohort studies: the Rotterdam Study (RS) (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013) and the Atherosclerosis Risk in Communities (ARIC) Study (1990Study ( -1992. We used the RS (n = 1,450) as the discovery panel and the ARIC Study (n = 2,097) as the replication panel. Linear mixed-effect models were used to assess the cross-sectional associations between genome-wide DNA methylation in leukocytes and body mass index (BMI) and waist circumference (WC), adjusting for sex, age, smoking, leukocyte proportions, array number, and position on array. The latter 2 variables were modeled as random effects. Fourteen 5′-C-phosphate-G-3′ (CpG) sites were associated with BMI and 26 CpG sites with WC in the RS after Bonferroni correction (P < 1.07 × 10 −7 ), of which 12 and 13 CpGs were replicated in the ARIC Study, respectively. The most significant novel CpGs were located on the Musashi RNA binding protein 2 gene (MSI2; cg21139312) and the leucyl-tRNA synthetase 2, mitochondrial gene (LARS2; cg18030453) and were associated with both BMI and WC. CpGs at BRDT, PSMD1, IFI44L, MAP1A, and MAP3K5 were associated with BMI. CpGs at LGALS3BP, MAP2K3, DHCR24, CPSF4L, and TMEM49 were associated with WC. We report novel associations between methylation at MSI2 and LARS2 and obesity-related traits. These results provide further insight into mechanisms underlying obesity-related traits, which can enable identification of new biomarkers in obesity-related chronic diseases.
Obesity is an important risk factor for cardiovascular disease, diabetes, some cancers, and musculoskeletal disorders (1-3). Evidence suggests that obesity not only is dependent on lifestyle factors but is a result of interactions between genes and lifestyle (4, 5) . Epigenetics has been proposed as a molecular mechanism that can affect the expression of genes by environmental influences and potentially could describe further the link between obesity and its complications (6) . Nevertheless, unlike genetics, DNA methylation is dynamic over time; therefore, change in DNA methylation could also be a consequence of obesity.
Epigenetics is the study of heritable variation in gene function that is not a result of a change in DNA sequence (7) . One of the best studied epigenetic mechanisms is DNA methylation, the attachment of a methyl group to a cytosine nucleotide of 5′-C-phosphate-G-3′ (CpG) dinucleotides. DNA methylation has varying functions at different locations in the human genome, including regulation of gene expression (8) . To date, epigenomewide association studies (EWAS) have identified several differentially methylated CpG regions related to body mass index (BMI)-the most widely used measure of obesity-and waist circumference (WC) (9) (10) (11) (12) . These few studies were performed in either patient populations, specific ethnic groups, or young adults. However, information on the older adults from populationbased studies is scarce. In older adults and elderly persons, biological mechanisms involved in body weight and body composition may be different from those in younger adults (13) . Therefore, it is crucial to explore the relationship of obesity to epigenetic variation in older adults.
We performed a cross-sectional EWAS of DNA methylation in blood leukocytes for BMI and WC in subjects from the Rotterdam Study (RS) and replicated our findings in the Atherosclerosis Risk in Communities (ARIC) Study.
METHODS

Study population
The RS is a large prospective, population-based cohort study aimed at assessing the occurrence of and risk factors for chronic diseases (cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric, dermatological, oncological, and respiratory) in the elderly (14) . The study comprises 14,926 subjects in total, living in the well-defined Ommoord district in the city of Rotterdam, the Netherlands. In 1989, the first RS cohort, Rotterdam Study I (RS-I), was established and comprised 7,983 subjects aged 55 years or above. In 2000, the second cohort, RS-II, was established, with 3,011 subjects who had reached the age of 55 years since 1989. In 2006, the third cohort, RS-III, was further included, with 3,932 subjects aged 45 years or above. The discovery panel for the current analysis consisted of a random sample of 1,450 participants from the first and second study visits of the third cohort (RS-III-1, RS-III-2) and the third study visit of the second cohort (RS-II-3).
We sought replication of the identified CpG sites in the ARIC Study, which is described in detail elsewhere (15) . Briefly, the ARIC Study is a prospective cohort study of cardiovascular disease in adults. Between 1987 and 1989, 7,082 men and 8,710 women aged 45-64 years were recruited from 4 US communities (15) . Methylation data were available in a subset of 2,097 African-American participants (10) .
The RS and ARIC Study protocols were approved by institutional review boards at each participating university, and all participants provided written informed consent.
Anthropometric measures and covariates
Height and weight were measured with the participant standing without shoes and heavy outer garments. WC was measured at the level midway between the lower rib margin and the iliac crest, with the participant in a standing position without heavy outer garments and with emptied pockets, breathing out gently. Hip circumference was recorded as the maximum circumference of the hips over the buttocks. BMI was calculated as weight (kg) divided by the square of height (m), and waist:hip ratio was calculated as WC divided by hip circumference (16) . Information on current and past smoking behavior was acquired from questionnaires.
DNA methylation data
DNA was extracted from whole peripheral blood (stored in ethylenediaminetetraacetic acid tubes) by means of standardized salting-out methods. Genome-wide DNA methylation levels were measured using the Illumina Infinium Human Methylation 450K BeadChip array (Illumina, Inc., San Diego, California) (17) . In short, samples (500 ng of DNA per sample) were first treated with bisulfite using the Zymo EZ-96 DNA methylation kit (Zymo Research, Irvine, California). Next, samples were hybridized to the arrays according to the manufacturer's protocol. The methylation proportion of a CpG site is reported as a β value ranging between 0 (no methylation) and 1 (full methylation). Data preprocessing was additionally performed in both data sets using an R programming pipeline that is based on the pipeline developed by Touleimat and Tost (18) , which includes additional parameters and options for preprocessing and normalizing methylation data directly from image data (IDAT) files. We excluded probes which had a detection P value greater than 0.01 in more than 95% of samples. We excluded 11,648 probes at X and Y chromosomes to avoid sex bias. The raw β values were then background-corrected and normalized using the "dasen" option in the wateRmelon R package (R Foundation for Statistical Computing, Vienna, Austria) (19) . Per individual probe, participants with methylation levels higher than 3 times the interquartile range were excluded.
Statistical analyses
The characteristics of the discovery and replication population are presented as mean values for continuous variables and proportions for categorical variables. In the discovery stage, we modeled cross-sectional associations between "dasen"-normalized β values of the CpG sites as the outcome and BMI or WC as the exposure, using linear mixed-effect models adjusting for age, sex, smoking, white blood cell proportion, array number (65 arrays), and position on array (12 positions; a combination of row number and column number). We performed an independent analysis in persons from RS-III-1, RS-III-2, and RS-II-3. We then performed a fixedeffects meta-analysis on the estimates for these 3 RS groups using the inverse-variance-weighted method implemented in METAL, combining the RS-III-1 participants with the RS-III-2 and RS-II-3 participants (20) . Technical covariates (array number and position on array) were modeled as random effects. For the RS-III-1 group, we estimated leukocyte proportions (B cells, CD4-positive T cells, CD8-positive T cells, granulocytes, monocytes, and natural killer cells) by means of a formula developed by Houseman et al. (21) and implemented in the minfi package in R (22) . For the RS-II-3 and RS-III-2 groups, we used white blood cell counts (i.e., lymphocytes, monocytes, and granulocytes), which were assessed with a Coulter Ac·T diff2 Hematology Analyzer (Beckman Coulter, Brea, California). We corrected for multiple testing using a robust Bonferroni-corrected P value of 1.07 × 10 −7 as the threshold for significance (0.05/463,456 probes).
The probes identified in the discovery analysis were tested for replication in the independent samples from the ARIC Study. A Bonferroni-corrected P value of 0.05 divided by the number of significant findings in the discovery study was used as a threshold level of significant replication. Finally, we checked all identified CpG sites for cross-reaction or polymorphism (23) . A CpG site was considered polymorphic when a single nucleotide polymorphism with a minor allele frequency greater than 0.01 resided at the position of the cytosine or guanine nucleotide or within 10 base pairs of the CpG site within the probe binding site (24) .
Methylation risk score
A methylation risk score was calculated based on CpG sites that were associated with the phenotypes. The effect estimates were used to build the methylation risk score using data from the discovery panel. Linear regression analyses were performed using BMI or WC as the outcome variable and the included CpG sites as exposure variables. With the use of linear regression models, we calculated the variance in lipid levels explained by the methylation risk score. Table 2 ) in the RS. In the ARIC Study, we successfully replicated 12 of the 14 BMI-related CpG sites (P < 3.57 × 10 −3 ) ( Table 2) and 13 of the 26 WC-related CpG sites (P < 1.92 × 10 −3 ) ( Table 3 ). Among these, 8 BMI-related CpG sites and 11 WCrelated CpG sites were novel. The most significant novel CpG sites were located on the Musashi RNA binding protein 2 gene (MSI2; cg21139312) and the leucyl-tRNA synthetase 2, mitochondrial gene (LARS2; cg18030453) for both BMI and WC. ), respectively. Additionally, for BMI, other novel CpG sites were located in the bromodomain testis associated gene (BRDT; cg03421440) and the microtubule associated protein 1A gene (MAP1A; cg15159104). For WC, the other top novel CpG sites were located in the transmembrane protein 49 gene (TMEM49; cg24174557) and the galectin 3 binding protein gene (LGALS3BP; cg04927537).
RESULTS
In addition to these novel findings, we confirmed previously reported associations of CpG sites with BMI and WC, including those on the carnitine palmitoyltransferase 1A gene (CPT1A), the adenosine triphosphate (ATP) binding cassette, subfamily G, member 1, gene (ABCG1), and the sterol regulatory element binding transcription factor 1 gene (SREBF1). Scatterplots of the associations between the replicated CpG sites and BMI and WC are shown in Web Figures 1 and 2 , respectively. Figure 1 shows successfully replicated findings for BMI and WC and highlights the overlapping loci, including those on ABCG1, MSI2, LARS2, SREBF1, and CPT1A. To test for genomic inflation, we calculated the λ value for the EWAS on BMI and WC and created Q-Q plots.
The λ values for the EWAS on BMI and WC were 1.487 and 1.556, respectively. The Q-Q plots for BMI and WC are shown in Web Figures 3 and 4 , respectively.
We calculated a methylation risk score based on the 12 CpG sites for BMI and 14 CpG sites for WC that were identified and replicated in the current study. For BMI, 2.0% of the variance was explained by the methylation risk score, whereas for WC the variance explained was 6.4%.
DISCUSSION
In this study, we used an EWAS approach to identify novel differentially methylated genes for obesity-related traits in older adults. The EWAS analysis in the RS data identified numerous novel loci associated with BMI and WC, of which many findings were successfully replicated in the ARIC data. The most significant CpG sites associated with both BMI and WC were located on the MSI2 and LARS2 genes. Additionally, CpG sites at BRDT and MAP1A were associated with BMI, and CpG sites at TMEM49 and LGALS3BP were associated with WC. Moreover, we confirmed previous findings that methylation at CPT1A, ABCG1, and SREBF1 is associated with BMI and WC.
Previous EWAS on obesity traits were conducted in population-based studies, including ARIC and the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study (9, 10) , and in persons with a history of myocardial infarction or healthy blood donors from the Cardiogenics Consortium (11) . Similarly to our findings, ARIC and GOLDN investigators reported an inverse association between a CpG site at CPT1A and BMI (9, 10) and positive associations of CpG sites at ABCG1 and SREBF1 with BMI and WC (10) . In the Cardiogenics Consortium, however, Dick et al. (11) reported only a positive association The methylation proportion of a 5′-C-phosphate-G-3′ site is reported as a β value ranging between 0 (no methylation) and 1 (full methylation). c Regression coefficient based on a linear mixed model and reflecting difference in the methylation β value per unit increase in BMI (kg/m 2 ). Models adjusted for age, sex, current smoking, leukocyte proportions, array number, and position on array.
d In the RS we corrected for multiple testing using a robust Bonferroni-corrected P value of 1.07 × 10 −7 , and in the ARIC Study the level of significance for replication was P < 3.57 × 10 An EWAS of Obesity-Related Traits 1665 between 3 CpG sites on the hypoxia inducible factor 3, α subunit, gene (HIF3A) and BMI in both blood and adipose tissue DNA in European adults. These CpG sites at HIF3A did not achieve the threshold for statistical significance in our study. However, CpG sites at HIF3A were replicated in the ARIC Study in DNA blood (10) . This discrepancy may be due to differences in the prevalences of obesity and comorbidity between our study (25% obesity, 11% diabetes, 7% coronary heart disease), the ARIC Study (44% obesity, 26% diabetes), and the Cardiogenics Consortium (4% diabetes, 52% myocardial infarction).
The genes known to be associated with obesity-CPT1A, ABCG1, and SREBF1-are involved in regulation of lipids, lipoprotein metabolism, and insulin sensitivity (25) (26) (27) . Specifically, CPT1A encodes for carnitine palmitoytransferase-1, which is a mitochondrial protein involved in fatty acid metabolism (28) and lipoprotein subfraction profile (26) . ABCG1 encodes for the ATP binding cassette, subfamily G, member 1, protein and is involved in the transport of cholesterol and phospholipids in macrophages (29) . Finally, SREBF1 encodes for sterol regulatory element binding transcription factor 1, which is known to promote adipocyte differentiation and signaling of insulin action (27) . Although it has been shown previously that these loci are associated with obesity-related traits, it is still important to replicate these findings across different study populations. Since the EWAS approach is hypothesis-free, findings are prone to being false-positive. By replicating previously reported results, we can say with more certainty that these CpG sites are truepositive findings.
In addition to confirming these previously identified loci, we have identified and replicated novel CpG sites located on the MSI2 (cg21139312) and LARS2 (cg18030453) genes, which were associated with both BMI and WC. The CpG site on MSI2 explained 2.2% of the variation in BMI and 8.2% of the variation in WC. MSI2 encodes RNA-binding proteins and plays a central role in posttranscriptional gene regulation (30) . A genomewide association study in pigs suggested that MSI2 is associated with eating behaviors, including number of visits to the feeder per day (31) . Moreover, in another study performed in mice, Sakakibara et al. (32) reported that MSI2 is linked with the proliferation and maintenance of stem cells in the central nervous system. This study suggested that during neurogenesis, MSI2 expression persisted in a subset of neuronal lineage cells, such as parvalbumin-containing γ-aminobutyric acid (GABA) neurons in the neocortex (30, 32) . GABA receptors are involved in controlling feeding behavior, reinforcing the role of MSI2 in obesity. The other novel locus associated with both BMI and WC, LARS2, encodes an enzyme that catalyzes aminoacylation of mitochondrial tRNALeu (33) . A previous postmortem study showed that LARS2 expression (human leucyl-tRNA synthetase 2, mitochondrial NM015340) was increased in brain tissue of patients with bipolar disorder as compared with controls (34) . Considering that bipolar disorder is associated with obesity, overweight, a The methylation proportion of a 5′-C-phosphate-G-3′ site is reported as a β value ranging between 0 (no methylation) and 1 (full methylation). b Regression coefficient based on a linear mixed model and reflecting difference in the methylation β value per unit increase in waist circumference (cm). Models adjusted for age, sex, current smoking, leukocyte proportions, array number, and position on array.
c In the RS we corrected for multiple testing using a robust Bonferroni-corrected P value of 1.08 × 10 −7 , and in the ARIC Study the level of significance for replication was P < 1.92 × 10 . and abdominal obesity (35) , methylation of MSI2 and LARS2 could play a role in disturbances in eating behaviors, and consequently in BMI and WC.
However, further studies are warranted to establish the temporality and pathway of the associations. Although previous investigators have studied the association between DNA methylation and anthropometric characteristics, this study is the first, to our knowledge, to have found an association between DNA methylation of several CpG sites, including those at MSI2 and LARS2, and BMI and WC. One possible explanation for discrepancies between the findings of our current study and those of previous similar studies is the difference in population characteristics. Study populations in previous studies consisted of mixed ethnic groups, participants of younger ages, or persons at high disease risk (9) (10) (11) (12) . Considering that our discovery cohort consisted of an ethnically homogenous group of older adults from the general population of Rotterdam, underlying mechanisms may differ from those in other population groups.
In this study, we conducted an EWAS in a European population and replicated the findings in African Americans. Epidemiologists have reported large disparities across racial/ethnic groups in the development of obesity (36) . For example, in the current study, the rates of obesity were significantly lower in Europeans (24.6%) than in African Americans (43.8%). However, despite the differences in ethnicity and prevalence of obesity between our studies, most of our CpG sites (86.7%) were successfully replicated in ARIC. This may indicate that, in contrast to genetic studies, where replication across ethnic groups is challenging due to differences in linkage disequilibrium pattern, epigenetic findings could more easily be translated across ethnic groups.
The strengths of the current study include the large size of the sample with available data on DNA methylation and the ability to replicate our findings in different ethnic populations. However, the results of this study must be interpreted in light of several limitations. We used whole blood samples for the quantification of DNA methylation, whereas adipose tissue may be a more relevant tissue for examining obesity. In this case, important CpG sites may not have been identified in our study. Unlike in genetic studies, unraveling the direction of the association between DNA methylation and phenotypes in epigenetic epidemiology remains challenging. Due to the cross-sectional study design and the nature of our variables, which are responsive to the environment and dynamic over time, a temporal direction in the association between DNA methylation and anthropometric measures cannot be determined. Because previous studies have shown that change in DNA methylation is a consequence of BMI for the majority of CpG sites, this may be the most likely direction for the associations observed in the current study as well (12) . However, longitudinal studies are required to confirm the direction of the associations between DNA methylation and anthropometric factors. Another possibility is that our findings could be explained by third common factors. For instance, associations may have been confounded by differences in cell type proportion. In order to avoid this source of confounding, we adjusted all analyses for cell type proportions. However, as in any observational study, residual confounding due to various lifestyle factors still remains an issue. Furthermore, the Q-Q plots showed high genomic inflation. Many EWAS studies have had high genomic inflation (37) . Adjustment for potential confounders such as technical covariates could decrease the inflation. Lehne et al. (38) have suggested that the correlation between CpG sites and the large number of findings in EWAS explain the residual inflation. In this study, we performed adequate adjustment for technical covariates. Moreover, the replication of our results in an independent population provides further evidence for the robustness of our findings.
In conclusion, we have reported a novel association of increased methylation in the MSI2 and LARS2 genes with increased BMI and WC in older adults. Moreover, we confirmed 3 previously identified methylation loci (CPT1A, ABCG1, and SREBF1) suggested to be associated with obesity. Further investigations using repeatedly measured genome-wide DNA methylation and obesity-related traits are needed to assess causality and to further evolve the growing field of epigenetic epidemiology toward novel therapeutic and preventative approaches to obesity and related noncommunicable disorders. 
